Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on March 17, 2021. The report addresses corporate governance changes effective as of the filing date. The company is designated as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Mark L. Baum resigned as a director effective March 17, 2021. The company stated there was no disagreement with the Company relating to its operations, policies, or practices.
- Director Appointment: Jenn Adams was appointed to the Board of Directors to fill the vacancy created by Mr. Baum's resignation. She is designated as a Class II director and will hold office until the 2023 Annual Meeting of Stockholders.
Management Commentary and Background
Ms. Adams brings significant industry experience to the Board. She is the Chief Executive Officer of August Bioservices LLC (since 2020), a provider of research, pharmaceutical development, and manufacturing services. Her prior roles include SVP & President of AmerisourceBergen's Clinical Product Solutions Business Unit and President of PharMEDium Services LLC. She also serves as an Executive in Residence/Senior Advisor to Oak HC/FT and holds an MBA from Northwestern University's J.L. Kellogg Graduate School of Management.
Key Facts for Investor Verification
- Confirm the effective date of Mark L. Baum's resignation and Jenn Adams' appointment (March 17, 2021).
- Verify Ms. Adams' tenure as a Class II director until the 2023 Annual Meeting.
- Review the attached press release (Exhibit 99.1) for additional details on the Board composition.
- Note that this filing contains no financial results or guidance updates.